Information for the public
Fedratinib (Inrebic) is available through the Cancer Drugs Fund. It is a possible treatment for an enlarged spleen (also known as splenomegaly) or other symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults who have previously had ruxolitinib.
More evidence on fedratinib is being collected, until results from the FREEDOM‑2 trial are available. After this NICE will decide whether or not to recommend fedratinib for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
If you are not eligible for fedratinib but are already having it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
These organisations can give you advice and support:
- Leukaemia Care, 08088 010 444
- MPN Voice, 07934 689 354, info@mpnvoice.org.uk
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-4383-8
This page was last updated: